CHICAGO -- Mifepristone (Korlym) reduced HbA1c levels in patients with inadequately controlled type 2 diabetes and ...

A study may have found a cure for type 1 diabetes. Here, experts explain how the treatment, zimislecel, works and what it ...

One-year results from the company's FORWARD-101 trial of islet cell therapy zimislecel (also known as VX-880) showed that all ...

US biopharma Vertex Pharmaceuticals and Japanese drugmaker Ono Pharmaceutical have announced an exclusive collaboration and ...

VX-880 stem cell therapy led to 92% reduction in insulin use, with 10 out of 12 patients eliminating injections entirely in a ...

"This edition of the Healthcare Enforcement column discusses two judicial decisions from recent months relating to the ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

In phase 2 of the FORWARD study, 83% of participants with type 1 diabetes achieved insulin independence a year after receiving zimislecel (formerly VX-880), an islet cell therapy developed ...

Vertex Pharmaceuticals locked arms with Ono Pharmaceutical in an exclusive deal to advance povetacicept, targeting B ...

As of 2021, 1.7 million adults in the United States were living with type 1 diabetes, according to statistics from the CDC.

OSAKA, Japan & BOSTON, MA, USA I June 23, 2025 I Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) and ...